MGMickaël Guedj

Mickaël Guedj

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mickaël Guedj has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Review of: "Strategies for Robust, Accurate, and Generalisable Benchmarking of Drug Discovery Platforms"

    by Mickaël Guedj

    This study presents a well-structured and highly relevant approach to improving benchmarking in computational drug discovery. The proposed optimizations to CANDO and the introduction of compbench, a head-to-head benchmarking framework, provide a nota...

  • Open Access

    Gaussian Mixture Models in R

    by Bastien Chassagnol, Antoine Bichat, Cheïma Boudjeniba, Pierre-Henri Wuillemin, Mickaël Guedj, David Gohel, Gregory Nuel, Etienne Becht


  • Open Access

    Industrializing AI-powered drug discovery: lessons learned from the Patrimony computing platform

    by Mickaël Guedj, Jack Swindle, Antoine Hamon, Sandra Hubert, Emiko Desvaux, Jessica Laplume, Laura Xuereb, Céline Lefebvre, Yannick Haudry, Christine Gabarroca, et al.

    As a mid-size international pharmaceutical company, we initiated 4 years ago the launch of a dedicated high-throughput computing platform supporting drug discovery. The platform named ‘Patrimony’ w...


  • Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer’s Disease

    by Serguei Nabirotchkin, Jan Bouaziz, Fabrice Glibert, Jonas Mandel, Julie Foucquier, Rodolphe Hajj, Noëlle Callizot, Nathalie Cholet, Mickaël Guedj, Daniel Cohen

    Background: Human diseases are multi-factorial biological phenomena resulting from perturbations of numerous functional networks. The complex nature of human diseases explains frequently observed marginal or transitory efficacy of mono-therapeutic interventions. For this reason, combination therapy is being increasingly evaluated as a biologically plausible strategy for reversing disease state, fostering the development of dedicated methodological and experimental approaches. In parallel, genome-wide association studies (GWAS) provide a prominent opportunity for disclosing human-specific therapeutic targets and rational drug repurposing. Objective: In this context, our objective was to elaborate an integrated computational platform to accelerate discovery and experimental validation of synergistic combinations of repurposed drugs for treatment of common human diseases. Methods: The proposed approach combines adapted statistical analysis of GWAS data, pathway-based functional annotation of genetic findings using gene set enrichment technique, computational reconstruction of signaling networks enriched in disease-associated genes, selection of candidate repurposed drugs and proof-of-concept combinational experimental screening. Results: It enables robust identification of signaling pathways enriched in disease susceptibility loci. Therapeutic targeting of the disease-associated signaling networks provides a reliable way for rational drug repurposing and rapid development of synergistic drug combinations for common human diseases. Conclusion: Here we demonstrate the feasibility and efficacy of the proposed approach with an experiment application to Alzheimer’s disease.


  • Open Access

    Network-based repurposing identifies anti-alarmins as drug candidates to control severe lung inflammation in COVID-19

    by Emiko Desvaux, Antoine Hamon, Sandra Hubert, Cheïma Boudjeniba, Bastien Chassagnol, Jack Swindle, Audrey Aussy, Laurence Laigle, Jessica Laplume, Perrine Soret, et al.

    While establishing worldwide collective immunity with anti SARS-CoV-2 vaccines, COVID-19 remains a major health issue with dramatic ensuing economic consequences. In the transition, repurposing existing drugs remains the fastest cost-effective approach to alleviate the burden on health services, most particularly by reducing the incidence of the acute respiratory distress syndrome associated with severe COVID-19. We undertook a computational repurposing approach to identify candidate therapeutic drugs to control progression towards severe airways inflammation during COVID-19. Molecular profiling data were obtained from public sources regarding SARS-CoV-2 infected epithelial or endothelial cells, immune dysregulations associated with severe COVID-19 and lung inflammation induced by other respiratory viruses. From these data, we generated a protein-protein interactome modeling the evolution of lung inflammation during COVID-19 from inception to an established cytokine release syndrome. This predictive model assembling severe COVID-19-related proteins supports a role for known contributors to the cytokine storm such as IL1β, IL6, TNFα, JAK2, but also less prominent actors such as IL17, IL23 and C5a. Importantly our analysis points out to alarmins such as TSLP, IL33, members of the S100 family and their receptors (ST2, RAGE) as targets of major therapeutic interest. By evaluating the network-based distances between severe COVID-19-related proteins and known drug targets, network computing identified drugs which could be repurposed to prevent or slow down progression towards severe airways inflammation. This analysis confirmed the interest of dexamethasone, JAK2 inhibitors, estrogens and further identified various drugs either available or in development interacting with the aforementioned targets. We most particularly recommend considering various inhibitors of alarmins or their receptors, currently receiving little attention in this indication, as candidate treatments for severe COVID-19.


  • Open Access

    An array CGH based genomic instability index (G2I) is predictive of clinical outcome in breast cancer and reveals a subset of tumors without lymph node involvement but with poor prognosis

    by Françoise Bonnet, Mickael Guedj, Natalie Jones, Sana Sfar, Véronique Brouste, Nabila Elarouci, Guillaume Banneau, Béatrice Orsetti, Charlotte Primois, Christine Tunon de Lara, et al.

    Background: Despite entering complete remission after primary treatment, a substantial proportion of patients with early stage breast cancer will develop metastases. Prediction of such an outcome remains challenging despite the clinical use of several prognostic parameters. Several reports indicate that genomic instability, as reflected in specific chromosomal aneuploidies and variations in DNA content, influences clinical outcome but no precise definition of this parameter has yet been clearly established. Methods: To explore the prognostic value of genomic alterations present in primary tumors, we performed a comparative genomic hybridization study on BAC arrays with a panel of breast carcinomas from 45 patients with metastatic relapse and 95 others, matched for age and axillary node involvement, without any recurrence after at least 11 years of follow-up. Array-CGH data was used to establish a two-parameter index representative of the global level of aneusomy by chromosomal arm, and of the number of breakpoints throughout the genome. Results: Application of appropriate thresholds allowed us to distinguish three classes of tumors highly associated with metastatic relapse. This index used with the same thresholds on a published set of tumors confirms its prognostic significance with a hazard ratio of 3.24 [95CI: 1.76-5.96] p = 6.7x10-5 for the bad prognostic group with respect to the intermediate group. The high prognostic value of this genomic index is related to its ability to individualize a specific group of breast cancers, mainly luminal type and axillary node negative, showing very high genetic instability and poor outcome. Indirect transcriptomic validation was obtained on independent data sets. Conclusion: Accurate evaluation of genetic instability in breast cancers by a genomic instability index (G2I) helps individualizing specific tumors with previously unexpected very poor prognosis.


  • Multiple Testing in Large-Scale Genetic Studies

    by Matthieu Bouaziz, Marine Jeanmougin, Mickaël Guedj

    Recent advances in Molecular Biology and improvements in microarray and sequencing technologies have led biologists toward high-throughput genomic studies. These studies aim at finding associations between genetic markers and a phenotype and involve conducting many statistical tests on these markers. Such Please confirm the changes in the sentence “Such a wide...” a wide investigation of the genome not only renders genomic studies quite attractive but also lead to a major shortcoming. That is, among the markers detected as associated with the phenotype, a nonnegligible proportion is not in reality (false-positives) and also true associations can be missed (false-negatives). A main cause of these spurious associations is due to the multiple-testing problem, inherent to conducting numerous statistical tests. Several approaches exist to work around this issue. These multiple-testing adjustments aim at defining new statistical confidence measures that are controlled to guarantee that the outcomes of the tests are pertinent.The most natural correction was introduced by Bonferroni and aims at controlling the family-wise error-rate (FWER) that is the probability of having at least one false-positive. Another approach is based on the false-discovery-rate (FDR) and considers the proportion of significant results that are expected to be false-positives. Finally, the local-FDR focuses on the actual probability for a marker of being associated or not with the phenotype. These strategies are widely used but one has to be careful about when and how to apply them. We propose in this chapter a discussion on the multiple-testing issue and on the main approaches to take it into account. We aim at providing a theoretical and intuitive definition of these concepts along with practical advises to guide researchers in choosing the more appropriate multiple-testing procedure corresponding to the purposes of their studies.


  • Open Access

    Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations

    by Guillaume Banneau, Mickaël Guedj, Gaëtan MacGrogan, Isabelle de Mascarel, Valerie Velasco, Renaud Schiappa, Valerie Bonadona, Albert David, Catherine Dugast, Brigitte Gilbert-Dussardier, et al.

    Introduction: Breast carcinoma is the main malignant tumor occurring in patients with Cowden disease, a cancer-prone syndrome caused by germline mutation of the tumor suppressor gene PTEN characterized by the occurrence throughout life of hyperplastic, hamartomatous and malignant growths affecting various organs. The absence of known histological features for breast cancer arising in a PTEN-mutant background prompted us to explore them for potential new markers. Methods: We first performed a microarray study of three tumors from patients with Cowden disease in the context of a transcriptomic study of 74 familial breast cancers. A subsequent histological and immunohistochemical study including 12 additional cases of Cowden disease breast carcinomas was performed to confirm the microarray data. Results: Unsupervised clustering of the 74 familial tumors followed the intrinsic gene classification of breast cancer except for a group of five tumors that included the three Cowden tumors. The gene expression profile of the Cowden tumors shows considerable overlap with that of a breast cancer subgroup known as molecular apocrine breast carcinoma, which is suspected to have increased androgenic signaling and shows frequent ERBB2 amplification in sporadic tumors. The histological and immunohistochemical study showed that several cases had apocrine histological features and expressed GGT1, which is a potential new marker for apocrine breast carcinoma. Conclusions: These data suggest that activation of the ERBB2-PI3K-AKT pathway by loss of PTEN at early stages of tumorigenesis promotes the formation of breast tumors with apocrine features.


  • Open Access

    Kerfdr: a semi-parametric kernel-based approach to local false discovery rate estimation

    by Mickael Guedj, Stephane Robin, Alain Celisse, Gregory Nuel

    The use of current high-throughput genetic, genomic and post-genomic data leads to the simultaneous evaluation of a large number of statistical hypothesis and, at the same time, to the multiple-testing problem. As an alternative to the too conservative Family-Wise Error-Rate (FWER), the False Discovery Rate (FDR) has appeared for the last ten years as more appropriate to handle this problem. However one drawback of FDR is related to a given rejection region for the considered statistics, attributing the same value to those that are close to the boundary and those that are not. As a result, the local FDR has been recently proposed to quantify the specific probability for a given null hypothesis to be true.